Gut Microbiota-Derived 5-HTP Shows Potential to Improve Autism Symptoms in Animal Models
New Research Links Gut Bacteria Metabolite to Autism Symptom Improvement
Recent scientific findings suggest that a compound produced by gut bacteria, 5-hydroxytryptophan (5-HTP), may help alleviate symptoms associated with autism spectrum disorder (ASD). This discovery sheds light on the complex interactions between the gut microbiome and the nervous system, offering a potential new avenue for therapeutic development.
Key Findings from Metagenomic and Metabolic Analyses
Researchers conducted comprehensive analyses of the gut microbiota in both human individuals diagnosed with ASD and mouse models exhibiting autism-like behaviors. Using shotgun metagenomic sequencing alongside targeted metabolic profiling via UPLC-MS/MS, they identified significant alterations in tryptophan metabolism within the gut bacteria communities.
Of particular interest was the identification of 5-HTP, a metabolite derived from tryptophan, produced by commensal gut bacteria. Experimental administration of 5-HTP to ASD mouse models resulted in measurable improvements in anxiety levels, repetitive and stereotypical behaviors, and social interaction deficits.
Mechanism: Crossing the Blood-Brain Barrier and Modulating Neural Pathways
The study demonstrated that 5-HTP can cross the blood-brain barrier, entering the central nervous system where it influences neural signaling. Specifically, 5-HTP was found to inhibit the overexpression of receptor tyrosine kinase (RTK) ligands. This action suppresses the downstream RTK/MAPK/ERK signaling pathway, which is implicated in the abnormal stabilization of dendritic spines in the hippocampus observed in certain ASD models, such as MeCP2 mutant mice.
By normalizing this signaling cascade, 5-HTP helps restore typical neural structure and function, which correlates with behavioral improvements.
Implications for ASD Treatment and Future Research
This study provides important insights into how gut microbiota-derived small molecules like 5-HTP may influence brain function and behavior. It supports the concept that modulating the gut microbiome could be a promising strategy to address neurodevelopmental conditions such as ASD.
However, these findings are currently based on animal models, and further research is needed to confirm safety, efficacy, and mechanisms in humans. Understanding the precise role of gut bacteria in neurodevelopmental disorders remains a complex challenge that requires cautious interpretation.
Conclusion
The identification of 5-HTP as a gut microbiota-produced compound capable of crossing into the brain and modulating neural pathways offers a novel perspective on ASD pathophysiology and treatment. This research underscores the potential of targeting the gut-brain axis in developing new interventions for autism spectrum disorder.
For more detailed information, see the original study published in Acta Pharmaceutica Sinica B: https://pubmed.ncbi.nlm.nih.gov/42764917/.
Download the images in this article
